Related Experiment Video
Updated: Aug 9, 2026
04:29
A Modified Simple Method for Induction of Myocardial Infarction in Mice
Published on: December 3, 2021
Oral contraceptives and myocardial infarction
1Department of Obstetrics and Gynecology, Tulane University, New Orleans, Louisiana.
American Journal of Obstetrics and Gynecology
|October 1, 1990
Summary
The risk of myocardial infarction for oral contraceptive users is primarily linked to smoking in women over 35. The cause is thrombotic, not atherosclerotic, with minor lipid changes being clinically irrelevant.
Area of Science:
- Cardiology
- Pharmacology
- Women's Health
Background:
- Oral contraceptives are widely used by women of reproductive age.
- Understanding the cardiovascular risks associated with oral contraceptive use is crucial for patient safety.
- Previous studies have suggested a link between oral contraceptives and myocardial infarction, but the specific risk factors and mechanisms require further clarification.
Purpose of the Study:
- To determine the specific risk factors for myocardial infarction in oral contraceptive users.
- To elucidate the underlying cause of myocardial infarction in this population.
- To assess the clinical relevance of lipid profile changes in oral contraceptive users concerning myocardial infarction risk.
Main Methods:
- This study analyzed data on oral contraceptive users and myocardial infarction events.
- Risk factors such as age and smoking status were evaluated.
- The etiological basis (thrombotic vs. atherosclerotic) of myocardial infarction was investigated.
- Lipid profiles of users were examined in relation to coronary plaque development.
Main Results:
- The risk of myocardial infarction in oral contraceptive users is confined to women older than 35 who smoke.
- Myocardial infarction in this group is attributed to thrombosis, not atherosclerosis.
- Observed minor changes in lipid profiles have no significant clinical impact on myocardial infarction risk.
- These lipid changes do not correlate with an increased incidence of coronary plaques.
Conclusions:
- Oral contraceptive use poses a significant myocardial infarction risk only in women over 35 who smoke.
- The thrombotic nature of myocardial infarction in oral contraceptive users highlights the importance of considering coagulation pathways.
- Routine monitoring of minor lipid changes is not clinically relevant for assessing myocardial infarction risk in oral contraceptive users.
Keywords:
Arterial Occlusive DiseasesArteriosclerosisAtherosclerosisBehaviorBiologyCardiovascular EffectsCholesterolContraceptionContraceptive Methods--side effectsDiseasesFamily PlanningHeart DiseasesLipid Metabolic EffectsLipidsLiterature ReviewMetabolic EffectsMyocardial InfarctionOral Contraceptives--side effectsPhysiologyResearch ReportSmokingVascular Diseases
Related Concept Videos
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:26Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...